Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.69 |
| ▸ | KMO | O15229 | 1/20 | 0.62 |
| ▸ | NOS3 | P29474 | 6/20 | 0.62 |
| ▸ | NOS1 | P29475 | 6/20 | 0.62 |
| ▸ | NOS2 | P35228 | 6/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14044191 | 0.87 | LMNA (0.59) | IDO1KMONOS3NOS1NOS2 | |
| SCHEMBL23964619 | 0.83 | IDO1 (0.69) | IDO1KMONOS3NOS1NOS2 | |
| SCHEMBL19398562 | 0.83 | IDO1 (0.67) | IDO1KMONOS3NOS1NOS2 | |
| SCHEMBL19831956 | 0.82 | IDO1 (0.62) | IDO1KMONOS3NOS1NOS2 | |
| SCHEMBL13367744 | 0.81 | MIF (0.66) | ALDH1A1 | |
| SCHEMBL14198758 | 0.81 | IDO1 (0.66) | IDO1KMONOS3NOS1NOS2 | |
| SCHEMBL616373 | 0.80 | SIGMAR1 (0.53) | IDO1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL8180452 | 0.80 | MIF (0.63) | IDO1ALDH1A1 | |
| SCHEMBL30336433 | 0.80 | SIGMAR1 (0.53) | IDO1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL13961602 | 0.80 | CD74 (0.64) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004064835-A1 | USE OF ION CHANNEL MODULATING AGENTS FOR TREATING PAIN | NEUROSEARCH A/S (DK) | 2004-08-05 | — | — | WO | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S. | 2004-02-12 | — | — | US | claimed |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-05-09 | — | — | US | claimed |
| EP-1144387-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-17 | — | — | EP | claimed |
| WO-2000034248-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| EP-3433234-B1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9840481-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| WO-2017165256-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1345618-B1 | CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS | SWITCH BIOTECH AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S. | 2004-02-12 | — | — | US | disclosed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-6624186-B2 | Modulators of SKCa, IKCa and BKCa channels. | NEUROSEARCH A/S (DK) | 2003-09-23 | — | — | US | disclosed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | disclosed |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-05-09 | — | — | US | disclosed |
| EP-1144387-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000034248-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | KCNJ2, KCNJ1, KCNJ11 | IDO1 1568/4885KMO 228/4885NOS3 2809/4885 |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | KCNJ2, KCNJ1, KCNJ11 | IDO1 1568/4885KMO 228/4885NOS3 2809/4885 |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | IDO1 495/4885KMO 364/4885NOS3 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.